Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.03 to $114.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.04 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F5 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.24 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F5 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F5 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.81 to $113.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.92 to $114.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F2 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.66 to $110.64 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.665 to $111.095 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.70 to $111.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F1 (shares): The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
Footnote F2 (price): In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Footnote F4 (shares): Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the… Full note on SEC EDGAR
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.36 to $114.34 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.365 to $115.295 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F5 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.37 to $115.82 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F6 (shares): The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
Footnote F7 (price): In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Footnote F8 (shares): Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the… Full note on SEC EDGAR
Footnote F10 (price): The closing price on September 1, 2026 was used to calculate the withholding obligation.
Footnote F1 (shares): The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
Footnote F2 (price): In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Footnote F4 (shares): Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the… Full note on SEC EDGAR
Footnote F6 (price): The closing price on September 1, 2026 was used to calculate the withholding obligation.
Footnote F1 (shares): The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
Footnote F2 (price): In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Footnote F4 (shares): Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the… Full note on SEC EDGAR
Footnote F6 (price): The closing price on September 1, 2026 was used to calculate the withholding obligation.
Footnote F1 (shares): The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
Footnote F2 (price): In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Footnote F4 (shares): Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the… Full note on SEC EDGAR
Footnote F6 (price): The closing price on September 1, 2026 was used to calculate the withholding obligation.
Footnote F9 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F10 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F11 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F12 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F13 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F14 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F15 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F1 (shares): The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
Footnote F2 (price): In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Footnote F4 (shares): Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the… Full note on SEC EDGAR
Footnote F6 (price): The closing price on September 1, 2026 was used to calculate the withholding obligation.
Footnote F2 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $125.00 to $125.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $126.00 to $126.23 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F2 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Footnote F5 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Footnote F2 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.00 to $110.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.01 to $112.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.51 to $112.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F2 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.00 to $116.54 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.50 to $114.58 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.92 to $113.455 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.49 to $115.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $105.305 to $106.2 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $106.75 to $107.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F5 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.71 to $110.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F6 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.96 to $113.89 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F7 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.305 to $115.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F8 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.35 to $116.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F9 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.35 to $117.3 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F10 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.41 to $118.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F11 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.42 to $119.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F12 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.42 to $120.41 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F13 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $120.49 to $120.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F2 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.20 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F5 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.31 to $89.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F3 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.19 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F5 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F6 (price): Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.25 to $89.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
CORCEPT THERAPEUTICS INC (CORT) had 28 insider filings in the last 90 days, with the most recent on 2026-10-05. The full record for CORT runs to 172 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CORT stock?
No insider purchases of CORT were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling CORT stock?
56 insider sales of CORT were filed in the last 90 days, totaling $52.80M.
Where can I see CORT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CORT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
Joseph Douglas Lyon - Officer
Sean Maduck - Officer
Gary Charles Robb - Officer
William Guyer - Officer
Atabak Mokari - Officer
